Business Wire

CO-WESTERN-UNION-COMPANY

6.2.2020 14:02:11 CET | Business Wire | Press release

Share
Western Union and Italy’s Postepay Enable Cross-Border Payments

Customers of App Postepay , among the preferred payment Apps in Italy, can now access Western Union’s cross-border and cross-currency platform to send money globally, following an agreement between Postepay , one of the largest Electronic Money Institution (EMI) in Italy, bringing together Poste Italiane’s assets and expertise in payments and telecommunications and Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement and payments.

More than seven million Postepay Evolution customers can now send money globally using Western Union via the Postepay App. They have the choice to fund their payments within the App using card or account and payout via Western Union’s Global Retail Network in over 200 countries and territories.

The integration of Western Union’s global cross-border, cross-currency money movement platform – including global settlement capabilities, network, compliance, and technology systems — enables international real-time cross-border transfers for financial institutions and service providers like Postepay, while globalizing services for their customers.

“It’s exciting to see two leading financial institutions working together to advance digital services for their customers by offering a seamless global cross-border payments experience,” said Hikmet Ersek, President and CEO, Western Union.

“Western Union’s open platform strategy allows us to innovatively connect the digital and physical worlds of money while helping leading organizations scale their services globally. We are delighted to welcome Postepay into the Western Union family,” he said.

Postepay SpA, a young company in the digital payments market, can count on a strong customer base of nearly 20 million of prepaid cards, more than 7 million of Postepay Evolution cards and more than 4,8 million of digital wallets. Postepay SpA is a center of excellence within the Poste Italiane Group.

“Postepay leads the country’s development and innovation by offering solutions that enable our customers to benefit from quality services and easy-to-use products,” said Marco Siracusano, Chief Executive Officer of Postepay.

“In line with our company’s strategy, Postepay’s first goal is to inform and guide changes in consumer habits while strongly investing and promoting our App based strategy. Therefore, the Postepay App offers our customer, not only highly performing dedicated services, but an ecosystem of integrated products and services which simplify transactions and exchanges at any level. Thanks to the collaboration with a leading brand such as Western Union our customers can now send money around the world in total comfort. In this context, a global leader such as Western Union, is the right partner to increase our growth,” he said.

“Summarizing the Postepay slogan, payments must be comfortable, simple and safe, and I believe that through this valuable partnership, we will be able to serve our respective customers even better,” concluded Marco Siracusano.

Remittances from Italy to the rest of the world in 2018 was USD 18.5 billion and into Italy USD 9.5 billion, according to the world bank .

WU-G

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of September 30, 2019, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2018, is available in 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .

About Postepay

Poste Italiane is one of Italy’s leading payment system providers, exploiting the Group’s integrated multichannel distribution platform based on its physical post office network and latest generation digital infrastructure. In 2018, the Company established Postepay SpA, the new company specializing in the development and processing of mobile and digital payments. Postepay SpA aims to consolidate its leadership and take advantage of the opportunities created by convergence between physical and digital channels, whilst at the same time supporting delivery of the Group’s overall strategy and guiding citizens, businesses and Public Administration entities through the transition from traditional payment systems to more advanced solutions. Postepay count on nearly 20 million of prepaid cards, more than 4,8 million e-wallets in use and nearly 4.5 million of SIM cards.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye